Citations

Clear

170 citation(s) found for "Limper, Andrew".

Myeloid C-type lectin receptors that recognize fungal mannans interact with Pneumocystis organisms and major surface glycoprotein
Hebrink, Deanne, Monteiro, João T. , Lepenies, Bernd , Carmona, Eva M. , Wuethrich, Marcel , Dias, Lucas dos Santos , Kottom, Theodore J. , Hebrink, Deanne M, Carmona, Eva M , Wüthrich, Marcel , Limper, Andrew H.

Mayo Clinic

Journal of Medical Microbiology | October 14, 2019 | Volume: 68 | Issue: 11 | Pages: 1649-1654

10.1099/jmm.0.001062 | PMID 31609198 Get It

Summary for Clinicians: Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice
Hage, Chadi A. , Carmona, Eva M. , Evans, Scott E. , Ruminjo, Joseph K., Thomson, Carey C. , Carmona, Eva M , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | September 17, 2019 | Volume: 16 | Issue: 12 | Pages: 1473-1477

10.1513/annalsats.201908-582cme | PMID 31526275 Get It

Metformin and Nintedanib Reduce Pulmonary Fibrosis in TGF-B Stimulated Fibroblasts
Vu, A. , Schaefbauer, Kyle, Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

B103. ILD: THERAPY | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A4090-A4090

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4090 Get It

Mortality Effect of the Anti-Fibrotics Pirfenidone and Nintedanib in Clinical Practice
Sangaralingham, Lindsey R. , Yao, Xing-Sheng, Dempsey, Timothy , Limper, Andrew H.

Mayo Clinic

C35. HEALTH SERVICES RESEARCH IN COUGH, CF, AND ILD | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A7393-A7393

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7393 Get It

Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib Among Commercially-Insured Adults in the United States
Sangaralingham, Lindsey R. , Dempsey, Timothy , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

D22. REAL WORLD MEDICATION USE IN PULMONARY DISEASES | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5920-A5920

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5920 Get It

Reply to Callahan: Identifying “Real” Patients in the Real World
Dempsey, Timothy , Limper, Andrew H. , Dempsey, Timothy M

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 16, 2019 | Volume: 201 | Issue: 2 | Pages: 257-258

10.1164/rccm.201908-1538le | PMID 31419393 Get It

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 24, 2019 | Volume: 200 | Issue: 9 | Pages: 1084-1085

10.1164/rccm.201907-1298ed | PMID 31339740 Get It

Diagnosis of Fungal Infections. A Systematic Review and Meta-Analysis Supporting American Thoracic Society Practice Guideline
Haydour, Qusay, Hage, Chadi A. , Carmona, Eva M. , Epelbaum, Oleg , Evans, Scott E. , Gabe, Luke M., Knox, Kenneth S. , Wengenack, Nancy L. , Murad, M. Hassan , Carmona, Eva M , Murad, M Hassan , Kolls, Jay K. , Prokop, Larry J. , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | June 20, 2019 | Volume: 16 | Issue: 9 | Pages: 1179-1188

10.1513/annalsats.201811-766oc | PMID 31219341 Get It

Abstract Rationale Prompt diagnosis of invasive fungal infections is important because of the associated morbidity and mortality; however, diagnosis is challenging because of the nonspecific symptoms and radiographic findings. Objectives To conduct a systematic review and meta-analysis of studies that evaluated the diagnostic accuracy of serum and bronchoalveolar lavage (BAL) galactomannan (GM) and serum or BAL polymerase chain reaction (PCR) in patients with suspected invasive aspergillosis (IA), β-d-glucan in critically ill patients at risk for candidiasis or candidemia, and serology testing and antigen detection in patients with endemic mycoses (histoplasmosis, blastomycosis, and coccidioidomycosis). Methods Studies were selected and appraised by pairs of reviewers. Bivariate random effects meta-analysis was used to generate pooled sensitivity, specificity, and diagnostic likelihood ratios. Results Serum GM in patients with impaired immunity suspected of having IA had sensitivity of 0.71 (95% confidence interval [CI], 0.64–0.78) and specificity of 0.89 (95% CI, 0.84–0.92). A cutoff of 1 optical density index yielded optimal sensitivity and specificity. BAL GM in patients with impaired immunity suspected of having IA had sensitivity of 0.84 (95% CI, 0.73–0.91) and specificity of 0.88 (95% CI, 0.81–0.91). Serum or whole-blood PCR in immunocompromised patients with suspected IA had sensitivity of 0.81 (95% CI, 0.73–0.86) and specificity of 0.79 (95% CI, 0.68–0.86). BAL PCR in patients at high risk for IA had high sensitivity of 0.90 (95% CI, 0.77–0.96) and specificity of 0.96 (95% CI, 0.93–0.98) for diagnosing IA. β-d-glucan assay in patients in the intensive care unit at risk for invasive candidiasis or candidemia had sensitivity of 0.81 (95% CI, 0.74–0.86) and specificity of 0.60 (95% CI, 0.49–0.71). Data on diagnostic accuracy of antigen detection and serology testing for endemic mycoses were limited and heterogeneous (varied according to test, patient immunity, and suspected endemic disease). Conclusions The diagnosis of invasive fungal infections remains a challenge. Various serum and BAL markers can aid in diagnosis. This evidence supports the development of clinical practice recommendations by the American Thoracic Society.
PD-1 hi CD8 + resident memory T cells balance immunity and fibrotic sequelae
Wang, Zheng , Wang, Shaohua , Goplen, Nick P., Li, Chaofan , Cheon, In Su , Dai, Qigang , Huang, Su, Shan, Jinjun , Ma, Chaoyu , Ye, Zhenqing , Xiang, Min , Porquera, Eva-Carmona, Kohlmeier, Jacob E. , Kaplan, Mark H. , Johnson, Aaron J. , Vassallo, Robert , Kohlmeier, Jacob E , Kaplan, Mark H , Zhang, Nu , Johnson, Aaron J. , Vassallo, Robert , Sun, Jie , Li, Chaofan , Dai, Qigang , Limper, Andrew H. , Porquera, E.M. Carmona, Sun, Jie

Mayo Clinic

Science Immunology | June 14, 2019 | Volume: 4 | Issue: 36 | Pages: No page available

10.1126/sciimmunol.aaw1217 | PMID 31201259 Get It

Exhausted-like CD8 + resident memory T cells in the lung limit immune activation–driven fibrosis.
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, Timothy , Sangaralingham, Lindsey R. , Yao, Xiaoxi , Sanghavi, Darshak , Shah, Nilay D. , Dempsey, Timothy M , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 31, 2019 | Volume: 200 | Issue: 2 | Pages: 168-174

10.1164/rccm.201902-0456oc | PMID 31150266 Get It

Abstract Rationale Since their approval, there has been no real-world or randomized trial evidence evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically important outcomes such as mortality and hospitalizations. Objectives To evaluate the clinical effectiveness of the antifibrotic medications pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Methods Using a large U.S. insurance database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1, 2018. A one-to-one propensity score–matched cohort was created to compare patients treated with antifibrotic medications (n = 1,255) with those not on treatment (n = 1,255). The primary outcome was all-cause mortality. The secondary outcome was acute hospitalizations. Subgroup analyses were performed to evaluate mortality differences by drug. Measurements and Main Results The use of antifibrotic medications was associated with a decreased risk of all-cause mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62–0.98; P value = 0.034). However, this association was present only through the first 2 years of treatment. There was also a decrease in acute hospitalizations in the treated cohort (HR, 0.70; 95% CI, 0.61–0.80; P value <0.001). There was no significant difference in all-cause mortality between patients receiving pirfenidone and those on nintedanib (HR, 1.14; 95% CI, 0.79–1.65; P = 0.471). Conclusions Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and hospitalization compared with no treatment. Future research should test the hypothesis that these treatments reduce early, but not long-term, mortality as demonstrated in our study.